title: Extreme hyperbilirubinemia associated with the use of anabolic steroids, health/nutritional supplements, and ethanol: response to ursodeoxycholic acid treatment.
authors.affiliation: Department of Medicine, Harborview Medical Center, University of Washington, Seattle, 98104 USA.
authors.forename: C
authors.initials: C
authors.lastname: Singh
authors.forename: P
authors.initials: P
authors.lastname: Bishop
authors.forename: R
authors.initials: R
authors.lastname: Willson
mesh_terms: D000328:Adult; D045930:Anabolic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001515:Beer / Q000009:adverse effects*; D005527:Food, Fortified / Q000009:adverse effects*; D058870:Food, Organic / Q000009:adverse effects*; D006801:Humans; D006932:Hyperbilirubinemia / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D009277:Nandrolone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077603:Nandrolone Decanoate; D008517:Phytotherapy; D013197:Stanozolol / Q000008:administration & dosage / Q000009:adverse effects; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*; D014891:Weight Lifting
chemical_list: D045930:Anabolic Agents; D013197:Stanozolol; D009277:Nandrolone; D014580:Ursodeoxycholic Acid; D000077603:Nandrolone Decanoate